88 completed, 16 terminated, 11 withdrawn, 10 recruiting. 146 Phase 2, 19 Phase 1, 11 Phase 3.
Follow aflibercept: new trials by email Literature Review of aflibercept trials Research Report on aflibercept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study Aflibercept Injection, Ahmed Tube Surgery - Glaucoma | Phase 2 | Not yet recruiting | University of Miami | 100 | 2026-12-01 | 2026-10-23 |
| A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration - Neovascular Age Related Macular Degeneration(nAMD) | Phase 2 | Not yet recruiting | Everest Medicines (China) Co.,Ltd. | 244 | 2026-11-01 | 2026-11-05 |
| A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema SB15 PFS - Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO | Phase 2 | Completed | Samsung Bioepis Co., Ltd. | 33 | 2026-09-07 | 2026-10-15 |
| Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration JWK001, Aflibercept (2.0 mg) - Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD | Phase 2 | Recruiting | West China Hospital | 50 | 2026-08-31 | 2026-08-20 |
| Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration AIV007, EYLEA® (aflibercept) Injection 2 mg (0.05mL) - Neovascular (Wet) Age-Related Macular Degeneration | Phase 2 | Recruiting | AiViva BioPharma, Inc. | 35 | 2026-07-01 | 2026-11-04 |
| Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy SCD411 0.05mL (2mg) - Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion | Phase 2 | Completed | Sam Chun Dang Pharm. Co. Ltd. | 33 | 2026-05-13 | 2026-06-08 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-04-15 | 2026-08-06 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-03-27 | 2026-10-02 |
| A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO Remigromig, Aflibercept 2.0 mg - Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO) | Phase 2 | Recruiting | EyeBiotech Ltd. | 160 | 2025-09-12 | 2026-10-20 |
| Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME) RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg) - Diabetic Macular Edema | Phase 2 | Recruiting | Sierra Eye Associates | 18 | 2025-03-18 | 2025-04-24 |
| Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD AL-001, Aflibercept - Wet Age-related Macular Degeneration (wAMD) | Phase 2 | Not yet recruiting | Beijing Anlong Biopharmaceutical Co., Ltd. | 40 | 2025-02-18 | 2025-02-21 |
| Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema Dapagliflozin, Anti-VEGF drug - Diabetic Macular Edema, Center-involved Diabetic Macular Edema | Phase 2 | Completed | Alexandria University | 56 | 2025-02-08 | 2026-10-26 |
| Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD SCT520FF, EYLEA 2 MG - nAMD | Phase 1 / Phase 2 | Recruiting | Sinocelltech Ltd. | 82 | 2024-11-26 | 2025-09-04 |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma ZIV-Aflibercept, Cemiplimab - Metastatic Uveal Melanoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2024-11-04 | 2025-12-04 |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only - Diabetic Retinopathy | Phase 2 | Recruiting | Boehringer Ingelheim | 175 | 2024-05-15 | 2026-10-28 |
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration KHK4951, Aflibercept Injection - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 170 | 2024-01-31 | 2026-10-14 |
| Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) LX102 subretinal injection, Aflibercept intravitreal injection - Neovascular Age-Related Macular Degeneration | Phase 2 | Active not recruiting | Innostellar Biotherapeutics Co.,Ltd | 50 | 2024-01-24 | 2026-03-06 |
| Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph - Diabetic Macular Edema | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 27 | 2024-01-15 | 2025-03-04 |
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema KHK4951, Aflibercept Injection - Diabetic Macular Edema (DME) | Phase 2 | Active not recruiting | Kyowa Kirin Co., Ltd. | 185 | 2024-01-09 | 2026-10-14 |
| Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant - Neovascular Age-related Macular Degeneration (nAMD) | Phase 1 / Phase 2 | Active not recruiting | Alcon Research | 139 | 2023-12-06 | 2026-08-27 |
Showing 20 of 146. Sign in to see all of them.
Macular Degeneration (23) · Colorectal Neoplasms (18) · Diabetic Retinopathy (16) · Choroidal Neovascularization (9) · Neoplasm Metastasis (9) · Diabetes Mellitus (7) · Rectal Neoplasms (7) · Retinal Diseases (6) · Eye Diseases (5) · Retinal Degeneration (5) · Retinal Vein Occlusion (5) · Wet Macular Degeneration (5) · Colonic Neoplasms (4) · Macular Edema (4) · Neoplasms (4)
National Cancer Institute (NCI) (15) · Regeneron Pharmaceuticals (9) · Sanofi (8) · Clearside Biomedical, Inc. (5) · EyeBiotech Ltd. (3) · Federation Francophone de Cancerologie Digestive (3) · Hospices Civils de Lyon (3) · Ophthotech Corporation (3) · AbbVie (2) · Alcon Research (2) · Arshad Khanani (2) · Dana-Farber Cancer Institute (2) · EyePoint Pharmaceuticals, Inc. (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Kyowa Kirin Co., Ltd. (2)
United States (98) · Germany (12) · Canada (10) · France (10) · Spain (9) · China (7) · Italy (7) · Puerto Rico (7) · United Kingdom (7) · Australia (6) · Hungary (6) · Japan (6) · South Korea (5) · Czechia (4) · Israel (4)
Ahmad Tarhini (2) · Raj K Maturi, MD (2) · Robert Coleman (2) · Sotaro Takigawa (2) · Susan Coultas, PhD (2) · Thomas Ciulla, MD (2) · Adam Rothman, MD (1) · Afsaneh Barzi (1) · Ahmad M Mansour, MD (1) · Ahmad Tarhini, MD, PHD (1)
PMID 37185961, PMID 16234465, PMID 19549103, PMID 19936307, PMID 20136420, PMID 20593550, PMID 21632852, PMID 21992853, PMID 22112608, PMID 22192729, PMID 22805331, PMID 22922531, PMID 24127346, PMID 24292447, PMID 25001321, PMID 25002722, PMID 25490004, PMID 25595177, PMID 25677668, PMID 26114826, PMID 27020759, PMID 27030277, PMID 27091810, PMID 27124775, PMID 28551167, PMID 28614154, PMID 30657223, PMID 30957581, PMID 31203498, PMID 31465088, PMID 31520559, PMID 31675952, PMID 31917731, PMID 31956432, PMID 32041720, PMID 32374423, PMID 32584384, PMID 32829304, PMID 32921581, PMID 33076864, PMID 33077475, PMID 33320223, PMID 33593448, PMID 33734306, PMID 33956075, PMID 34620799, PMID 35768859, PMID 35822428, PMID 36395401, PMID 36604756
N01CM62209 (5), 2014 (3), 2019 (2), N01CM62201 (2), N01CM62203 (2), P30CA033572 (2), 2015 (1), 2018 (1), 2023 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM62204 (1), N01CM62206 (1)